



# CELL-BASED IMMUNO-ONCOLOGY WORKSHOP

## DAY 1 – SEPTEMBER 5, 2024

- 8:00 – 8:45am      **Registration & Breakfast**
- 8:45 – 9:10am      **Opening Remarks**  
**Michael Lehmicke**, SVP, Science and Industry Affairs, ARM
- 9:10 – 9:40am      **CAR T Cell Successes, Challenges, and Future Prospects**  
**Bruce Levine**, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania School of Medicine
- 9:40 – 10:00am      **Enhancing Patient Centricity and Maximizing Data Collection for Long-term Follow-up Requirements**  
**Lana Shiu**, Global Head of Regulatory Affairs, Kite Pharma
- 10:00 – 10:20am      **Novel Donor Assessment Tool for Better Functional Characterization of Donor Starting Material**  
**Robert Tressler**, Chief Scientific Officer, Excellos
- 10:20 – 10:40am      **Morning Break**
- 10:40 – 11:10am      **CAR-T in Action: Outpatient Therapies may Relieve the Anticipated Traffic Jams**  
**David Porter**, Director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, University of Pennsylvania School of Medicine
- 11:10 – 11:30am      **Emerging Opportunities and the Current Regulatory Landscape for Cell-Based IO Developers**  
**Dylan Bechtle**, Associate Director, Regulatory Policy and Intelligence, J&J
- 11:30 – 12:30pm      **Panel Discussion: Commercialization & Access Challenges**  
**George Eastwood**, Chair, Board of Directors, Emily Whitehead Foundation  
**Rebecca Poehnelt**, VP, Global Oncology Cell Therapy Commercial Strategy, J&J  
**Robert Richards**, Corporate Director, Cell Therapy and Transplant Program, University of Pennsylvania School of Medicine  
**Robert Shelley**, VP, US Health Systems and Market Access, Kite Pharma
- 12:30 – 2:00pm      **Lunch Break**
- 2:00 – 2:20pm      **Regulatory Considerations: CAR-T Cell Therapies for Hematological Malignancies**  
**Upendra Mahat**, Clinical Team Lead, Division of Clinical Evaluation Hematology, Office of Therapeutics Product, FDA CBER
- 2:20 – 2:40pm      **Advancing T<sub>SCM</sub>-rich Allogeneic CAR-T Therapies – Early Data Demonstrate Compelling Efficacy, Safety and Manufacturing Reliability Profile**  
**Syed Rizvi**, Chief Medical Officer, Poseida Therapeutics
- 2:40 – 3:00pm      **Allogeneic, Directed NK Cell Therapy – Highlighting an iPSC-derived CAR-Directed Approach**  
**Adrienne Farid**, COO & Head of Early Development, Century Therapeutics

3:00 – 3:20pm **Chimeric ILT-Receptor NK (CIR-NK) Cell Technology Effectively Targets HLA-G in Hematologic and Solid Tumors**  
**J. Henri Bayle**, CSO, CDO, Co-founder, NKILT Therapeutics

3:20 – 3:30pm **Day 1 Concluding Remarks**  
**Michael Lehmicke**, SVP, Science and Industry Affairs, ARM

## DAY 2 – SEPTEMBER 6, 2024

8:00 – 8:45am Registration & Breakfast

8:45 – 8:50am **Day 2 Opening Remarks**  
**Michael Lehmicke**, SVP, Science and Industry Affairs, ARM

8:50 – 9:20am **T Cell Therapy 2024: "Faster, Higher, Stronger"**  
**Cassian Yee**, Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center

9:20 – 9:40am **Development Considerations for Engineered TCR-T Cell Therapies for Solid Tumors**  
**Dennis Williams**, SVP, Late Stage Development, Adaptimmune

9:40 – 10:00am **Multiplex Gene Editing for the Discovery and Implementation of Enhanced CAR and TCR-T Cell Therapies for Solid Tumors**  
**Aaron Prodeus**, Director, Cell Therapy Pipeline & Cell Engineering, Intellia Therapeutics

10:00 – 10:20am **Integrated Discovery and Manufacturing for Systematised Product Development across the TCR-T Target Space**  
**Reagan Jarvis**, CEO & Co-founder, Anocca

10:20 – 10:40am Morning Break

10:40 – 11:10am **Intrathecal Delivery of Bicistronic CAR T Cells Leads to Significant Activity in Recurrent GBM Patients**  
**Zev Binder**, Research Assistant Professor, Department of Neurosurgery, University of Pennsylvania School of Medicine

11:10 – 11:30am **Comparability Study Considerations in the Development and Approval of AMTAGVI™ (lifileucel)**  
**Arvind Natarajan**, SVP, Process and Analytical Development, Iovance Biotherapeutics

11:30 – 11:50am **CAR-M: Engineering Myeloid Cells for Cancer Immunotherapy**  
**Gene Kennedy**, Chief Medical Officer, Carisma Therapeutics

11:50 – 1:00pm Lunch Break

1:00 – 2:00pm **Panel Discussion: Manufacturing & Scaling Considerations**  
**Bruce Thompson**, CEO, Kincell Bio (*moderator*)  
**Eytan Abraham**, VP, Business Head of Cell, Gene and Nucleic Acids Franchises, Resilience  
**Chris Heery**, Chief Medical Officer, Arcellx  
**Audrey Greenberg**, Co-Founder & Chief Business Officer, Center for Breakthrough Medicines, SK pharmteco  
**Will Zhou**, Head of US CAR-T Operations, J&J

2:00 – 2:15pm **Day 2 Concluding Remarks**  
**Michael Lehmicke**, SVP, Science and Industry Affairs, ARM